Effect of vitamin D-binding protein genotype on the development of asthma in children

Aledie Navas-Nazario1, Fang Yong Li2, Veronika Shabanova2

  • 1Section of Respiratory Medicine, Department of Pediatrics, Yale School of Medicine, New Haven, Connecticut.

Insights

Certain vitamin D-binding protein gene variants may protect children from developing asthma. The GC genotype ET/ET (Gc1s/Gc1s) showed a protective effect against asthma in a Hispanic population.

Area of Science:

  • Genetics
  • Immunology
  • Pediatrics

Background:

  • Vitamin D's role in inflammatory diseases like asthma is debated.
  • Vitamin D-binding protein (VDBP) transports vitamin D metabolites.
  • Genetic variations in the GC gene (encoding VDBP) influence vitamin D metabolite levels.

Purpose of the Study:

  • To investigate if specific GC gene single nucleotide polymorphisms (SNPs) predict asthma development in children.
  • To test the hypothesis that GC SNPs encoding D432E and T436K variants are associated with asthma risk.

Main Methods:

  • Retrospective review of medical records for 776 children.
  • Analysis of GC genotype, VDBP concentration, and 25-hydroxyvitamin D levels at 6-36 months of age.
  • Data collection included demographics, clinical data, and asthma diagnosis criteria.

Main Results:

  • GC genotype data was available for 463 children.
  • Asthma was diagnosed in 26% of the subjects.
  • The GC genotype encoding the ET/ET (Gc1s/Gc1s) variant was associated with lower odds of asthma development in the Hispanic population, suggesting a protective effect.

Conclusions:

  • In a Hispanic population, the ET/ET (Gc1s/Gc1s) genotype of VDBP may offer protection against asthma.
  • This contrasts with the wild-type DT/DT (Gc1f/Gc1f) genotype.
Abstract

Related Concept Videos

Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
112
Factors Affecting Protein-Drug Binding: Patient-Related Factors01:29

Factors Affecting Protein-Drug Binding: Patient-Related Factors

Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
475
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
159
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.5K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.7K